

# 

## Background:

- · Mindfulness meditation and related interventions have demonstrated therapeutic potential for addiction<sup>1</sup>, anxiety<sup>2</sup>, stress<sup>3</sup> and depression<sup>2</sup> and enhancements in well-being<sup>4,5</sup>
- Psychedelics have been successfully applied to addiction<sup>6</sup>, depression<sup>7,8</sup>, anxiety<sup>6</sup>, eating disorders<sup>9</sup> and give rise to lasting benefits in healthy population<sup>10,11</sup>
- · Due to their common effects and various shared therapeutic mechanisms, these two interventions have been suggested to induce complementary effects if combined<sup>12</sup>.



Ī	Evidence for synergistic Effects					
l	Study	Substance	Sample (size)	Study design	Findings	
	Griffiths et al. (2018)	Psilocybin	Healthy sample (n=75)	2 sessions (or active control) combined with moderate/high intensity 6-month programme of spiritual practices; DB, R, PC, WS+BS	<ul> <li>↑mood, well-being + life satisfaction &gt; control group</li> <li>↑Life meaning, ↑Trait forgiveness, ↑Spirituality, ↑Daily transcendental experience, ↑Positive Attitudes about Oneself ↑Interpersonal closeness and ↑Gratitude 4 months after last psilocybin session for experimental group, compared to baseline</li> <li>Engagement in Daily Meditation, ↑Meditation Duration, ↑ Frequency of Spiritual Awareness Practice, ↑Engagement in Daily Spiritual Practice &amp; ↑Frequency of Journal Writing 4 months after last psilocybin session for experimental group, compared to baseline</li> <li>→Unprecedented trait changes produced: failed to be demonstrated after psilocybin without mindfulness<sup>13,14,15</sup></li> </ul>	
	Smigielski et al. (2019a)	Psilocybin	Healthy sample of experienced mind-fulness	Single session during 5- day Zen meditation retreat; DB, R, PC, WS +	<ul> <li>↑ Appreciation for life, ↑Self-Acceptance, ↑Quest for meaning, ↓Fear of Death, + ↑Trait Mindfulness 4 months after retreat &gt; control group</li> <li>↑ Meditation Depth on the day of administration</li> </ul>	

- retreat; DB, R, PC, WS + ↑Meditation Depth on the day of administration →Unprecedented trait changes produced: failed to be demonstrated after psilocybin without mindfulness<sup>13,14,15</sup>
  - x5 abstinence rates for experimental group, x7.8 less likely to relapse than control
  - 44% abstinence maintained at 6-month follow-up vs. 0% for control group →Extended ketamine's anti-addictive effects, which had only been reported transiently 16,17

DB: Double-blind; R: Randomized; PC: Placebo-Controlled; WS: Within-Subject comparison; BS: Between-Subject comparison

administered once

programme

during 5-week MBRP

BS

#### **Conclusions:**

Dakwar et

al. (2019)

- These studies provide promising evidence for complementary effects between mindfulness meditation and psychedelic administration
- Evidence is preliminary and requires replication

meditators

Ketamine Clinical sample at I.V. Ketamine

risk of cocaine

addiction (n=55)

(n=25)

Depression could benefit the most from a combined methodology

## Mechanisms underlying synergistic effects:

- Anti-depressive/Anxiolytic Effects
  - · Demonstrated effectively for MBCT, ketamine, ayahuasca and psilocybin
  - Psychedelics also led to  $\Psi$  symptomatology in healthy volunteers
  - Subserved by psychological effects neurogenesis, which has been observed for both interventions

### Mystical Experiences

- Predicted therapeutic benefit in both interventions
- · Mindfulness intensified mystical experiences in combined designs

#### Psychological Mechanisms

flexibility, Cognitive flexibility, emotional decentering, nonattachment



Figure 1: Psychological benefits of mindfulness meditation training (Tang et al., 2017)

 Acceptance features are enhanced by mindfulness training and some psychedelics and can in turn  $\psi$ psychopathology

#### **Neuromodulatory Changes**

- Acute disruption of the Default Mode Network
- Long-term enhancements of dynamic global brain connectivity
- Tharmony between DMN and TPN networks




Figure 2: The human Default Mode Network (DMN) (MCCormick & Telzer, 2018)